Notis-McConarty Edward’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,700
| Closed | -$263K | – | 80 |
|
|
2024
Q4 | $263K | Sell |
2,700
-1,015
| -27% | -$108K | 0.13% | 74 |
|
|
2024
Q3 | $427K | Sell |
3,715
-7,146
| -66% | -$811K | 0.19% | 60 |
|
|
2024
Q2 | $1.16M | Sell |
10,861
-13,300
| -55% | -$1.34M | 0.45% | 49 |
|
|
2024
Q1 | $2.34M | Sell |
24,161
-12,570
| -34% | -$1.29M | 0.92% | 33 |
|
|
2023
Q4 | $3.71M | Sell |
36,731
-5,320
| -13% | -$514K | 1.48% | 27 |
|
|
2023
Q3 | $4.28M | Sell |
42,051
-940
| -2% | -$95.4K | 1.74% | 23 |
|
|
2023
Q2 | $4.34M | Sell |
42,991
-250
| -0.6% | -$25K | 1.65% | 22 |
|
|
2023
Q1 | $3.98M | Sell |
43,241
-440
| -1% | -$38.4K | 1.58% | 24 |
|
|
2022
Q4 | $3.96M | Sell |
43,681
-15
| -0% | -$1.26K | 1.65% | 22 |
|
|
2022
Q3 | $3.32M | Sell |
43,696
-443
| -1% | -$36.7K | 1.49% | 23 |
|
|
2022
Q2 | $3.73M | Buy |
44,139
+145
| +0.3% | +$12.7K | 1.55% | 20 |
|
|
2022
Q1 | $3.86M | Buy |
43,994
+80
| +0.2% | +$6.93K | 1.38% | 24 |
|
|
2021
Q4 | $3.84M | Sell |
43,914
-1,997
| -4% | -$166K | 1.28% | 26 |
|
|
2021
Q3 | $3.75M | Buy |
45,911
+1,685
| +4% | +$152K | 1.38% | 25 |
|
|
2021
Q2 | $4.03M | Sell |
44,226
-614
| -1% | -$54.7K | 1.49% | 23 |
|
|
2021
Q1 | $3.83M | Buy |
44,840
+250
| +0.6% | +$22.4K | 1.49% | 24 |
|
|
2020
Q4 | $4.21M | Buy |
44,590
+645
| +1% | +$56.4K | 1.71% | 20 |
|
|
2020
Q3 | $3.82M | Buy |
43,945
+160
| +0.4% | +$13.9K | 1.68% | 19 |
|
|
2020
Q2 | $3.82M | Buy |
43,785
+580
| +1% | +$50.1K | 1.78% | 18 |
|
|
2020
Q1 | $3.56M | Buy |
43,205
+255
| +0.6% | +$22.8K | 1.97% | 17 |
|
|
2019
Q4 | $4.07M | Sell |
42,950
-180
| -0.4% | -$16.2K | 1.81% | 20 |
|
|
2019
Q3 | $3.75M | Sell |
43,130
-365
| -0.8% | -$32.8K | 1.76% | 20 |
|
|
2019
Q2 | $3.97M | Sell |
43,495
-5,018
| -10% | -$425K | 1.87% | 20 |
|
|
2019
Q1 | $4.18M | Buy |
48,513
+173
| +0.4% | +$13.9K | 2.02% | 20 |
|
|
2018
Q4 | $3.72M | Sell |
48,340
-173
| -0.4% | -$13.5K | 2.05% | 17 |
|
|
2018
Q3 | $3.75M | Buy |
48,513
+2,260
| +5% | +$167K | 2% | 21 |
|
|
2018
Q2 | $3.13M | Buy |
46,253
+1,468
| +3% | +$101K | 1.85% | 21 |
|
|
2018
Q1 | $3.25M | Buy |
44,785
+898
| +2% | +$68.4K | 1.94% | 20 |
|
|
2017
Q4 | $3.3M | Buy |
43,887
+4,576
| +12% | +$345K | 1.9% | 22 |
|
|
2017
Q3 | $3.02M | Buy |
39,311
+279
| +0.7% | +$21.1K | 1.89% | 20 |
|
|
2017
Q2 | $2.92M | Buy |
39,032
+80
| +0.2% | +$5.67K | 1.89% | 20 |
|
|
2017
Q1 | $2.59M | Buy |
38,952
+2,232
| +6% | +$149K | 1.7% | 20 |
|
|
2016
Q4 | $2.4M | Sell |
36,720
-2,256
| -6% | -$146K | 1.65% | 21 |
|
|
2016
Q3 | $2.76M | Buy |
38,976
+334
| +0.9% | +$24.3K | 1.88% | 19 |
|
|
2016
Q2 | $2.86M | Buy |
38,642
+296
| +0.8% | +$20.4K | 2% | 16 |
|
|
2016
Q1 | $2.49M | Buy |
38,346
+419
| +1% | +$28.5K | 1.77% | 20 |
|
|
2015
Q4 | $2.92M | Sell |
37,927
-274
| -0.7% | -$21.8K | 2.1% | 15 |
|
|
2015
Q3 | $3.15M | Buy |
38,201
+503
| +1% | +$44.8K | 2.35% | 10 |
|
|
2015
Q2 | $3.32M | Buy |
37,698
+1,928
| +5% | +$177K | 2.25% | 12 |
|
|
2015
Q1 | $3.16M | Buy |
35,770
+2,065
| +6% | +$183K | 2.19% | 12 |
|
|
2014
Q4 | $2.8M | Buy |
33,705
+1,646
| +5% | +$136K | 1.91% | 14 |
|
|
2014
Q3 | $2.7M | Sell |
32,059
-3,471
| -10% | -$281K | 1.9% | 17 |
|
|
2014
Q2 | $2.88M | Buy |
35,530
+809
| +2% | +$63.6K | 1.91% | 16 |
|
|
2014
Q1 | $2.65M | Buy |
34,721
+223
| +0.6% | +$16.3K | 1.84% | 17 |
|
|
2013
Q4 | $2.48M | Buy |
+34,498
| New | +$2.4M | 1.74% | 21 |
|
Other funds holding NVS
Notis-McConarty Edward's NVS Position: Q1 2025 in Review
Notis-McConarty Edward sold out of Novartis (NVS) in Q1 2025, closing a stake of 2,700 shares — an estimated $263K sold.
Notis-McConarty Edward first reported a position in NVS in Q4 2013 and held it in 45 quarters. The position peaked at $4.34M in Q2 2023. 1,356 funds tracked by Wall St. Rank hold NVS as of Q1 2025.
- Notis-McConarty Edward reported no remaining Novartis position as of Q1 2025 after selling out during the quarter.
- Notis-McConarty Edward sold 2,700 Novartis shares in Q1 2025, an estimated $263K.
- Notis-McConarty Edward first reported a position in Novartis in Q4 2013 and held it in 45 quarters.
- Notis-McConarty Edward's Novartis position peaked at $4.34M in Q2 2023.
- 1,356 funds tracked by Wall St. Rank held Novartis as of Q1 2025.
Based on Notis-McConarty Edward's 13F filing for Q1 2025, filed 6 May 2025.